Generic Oncology Drugs Market Worth US$ 36,029.60 Mn in 2027 - Lead By Glenmark, MSN Laboratories, Aurobindo Pharma, Zydus Cadila, Mylan, Cipla

Cancer is one of the leading cause of deaths across the globe and is extremely affecting the quality of life. Thus, cancer will be burden on society if not diagnosed and treated on time. According to the World Health Organization in 2018, approximately, 9.6 million deaths across the globe were due to cancer. Furthermore, the National Cancer Institute predicted that in 2018, approximately 1,735,350 new cancer cases will be diagnosed in the US. Furthermore, Asia Pacific region is also facing the problem of growing prevalence of cancer. The top 15 countries with Cancer prevalence are: Japan, Taiwan, Singapore, South Korea, Malaysia, Thailand, China, Philippines, Sri Lanka, Vietnam, Indonesia, Mongolia, India, Laos, and Cambodia. According to the National Institute of Cancer Prevention and Research (NICPR), in 2018, in India total deaths due to cancer were 784,821. These statistics determine an increase in the demand for advanced cancer diagnostics in various regions across the globe. Thus driving the growth of generic oncology drugs during the forecast period.

Get sample PDF Brochure of Generic Oncology Drugs Market study Here http://bit.ly/2WBJfQT

The global generic oncology drugs market, based on the molecule type was segmented into small molecule and large molecule. In 2018, the small molecule segment held a largest market share of 87.67% of the generic oncology drugs market, by molecule type. The advantages of small molecules in terms of their complexity and molecular size that can traverse throughout reach to target site and show its effective action as well as advent of personalized drug development are the major factors to likely account for the growth of the segment over the years to come. However, the same segment is expected to witness the highest CAGR of 6.6% over the coming years.

Some of the prominent players operating in the generic oncology drugs market are Teva Pharmaceutical Industries Ltd., Sandoz International GMBH, Glenmark, Sun Pharmaceutical Industries Ltd, MSN Laboratories, Aurobindo Pharma, Intas Pharmaceuticals, Zydus Cadila, Mylan N.V., Cipla Inc., Fresenius Kabi AG, and Dr. Reddy's Laboratories Ltd., among others. The market players are focused on bringing new and innovative products and services through various inorganic strategies such as acquisitions and mergers to sustain their position in the market. Recently in July 2019, Drug maker Pfizer Inc. has agreed to spin off its generic drugs business and combine it with Mylan, a move that leaves Pfizer with more profitable innovative drugs, including cancer drug Ibrance and pneumonia vaccine Prevnar

Product launches, agreements, and acquisitions were observed as the most adopted strategy in the global generic oncology drugs market industry. For instance, in July 2019, Sandoz announced the launch of the generic oncology medicine gefitinib indicated for adult patients with locally advanced or metastatic non-small cell lung cancer with activating mutations of EGFR-TK, which is recommended by ESMO as first-line treatment. Moreover, in September 2016, Glenmark Pharmaceuticals entered into an agreement with US-based Particle Sciences Inc. to develop and market a generic version of Celgene's ABRAXANE which is used in treatments of breast and lung cancers.

Introduction

1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Global Generic Oncology Drugs Market - By Molecule Type
1.3.2 Global Generic Oncology Drugs Market - By Application
1.3.3 Global Generic Oncology Drugs Market - By Geography
2. Global Generic Oncology Drugs Market - Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Global Generic Oncology Drugs- Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America PEST Analysis
4.2.2 Europe PEST Analysis
4.2.3 Asia Pacific - PEST Analysis
4.2.4 Middle East & Africa- PEST Analysis
4.2.5 South & Central America - PEST Analysis
4.3 Expert Opinions
5. Global Generic Oncology Drugs Market - Key Industry Dynamics
5.1 Key Market Drivers
5.1.1 Growing Cancer Prevalence Across The Glob
5.1.2 New Drug Launches
5.1.3 Benefits Offered By Generic Drugs
5.2 Key Market Restraints
5.2.1 Pricing Pressure
5.3 Key Market Opportunities
5.3.1 Growing Pharmaceutical Industry in Emerging Economies
5.4 Future Trends
5.4.1 Inclination Towards Personalized Medicine
5.5 Impact Analysis

Purchase Copy of This Report @ http://bit.ly/2QsjXR8

About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.

Contact Us:
Call: +1-646-491-9876
Email: sales@theinsightpartners.com

This release was published on openPR.